Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
GILT heads into the week of November 11 earnings with shorts rebuilding, borrow costs at a one-month high, and the stock down sharply against peers that are mostly rising.
The borrow market tells the most pointed story this week. Cost to borrow nearly doubled over the past seven days, jumping 74% to roughly 4.6%, its highest level since late September. That move came alongside short interest climbing to 3.6% of the free float, up 18% over the past month. Availability has loosened slightly from extremely tight readings seen in mid-September, when it hit just 5.5%, the tightest point of the past year. It now reads at about 32%, meaning roughly one share remains available for every three already borrowed. That is still a moderately tight lending market, not a crisis, but the combination of rising shorts and rising borrow costs suggests demand to be short is outpacing supply in a meaningful way.
Options positioning offers little counterweight to that picture. The put/call ratio runs at 0.30, barely a whisker above its 20-day average of 0.29, and the z-score of 0.13 is statistically unremarkable. The 52-week high on the PCR is 0.63, so the current reading is well below peak defensiveness. Options traders are not adding to the cautious tone that the borrow market implies.
The Street remains broadly constructive on paper, but the data is growing stale. The most recent analyst moves on record are from February 2026, when Needham reiterated its Buy at $20 and Freedom Broker upgraded to Buy with an $18 target. The consensus mean price target of $19.20 implies substantial upside from the current $9.22 close, but with the analyst data now eight months old and the stock down roughly 46% from those target levels, readers should treat those figures as dated rather than current guidance. The bull case centres on defence bookings and a clean balance sheet. The bear case focuses on commercial segment weakness and intensifying competition from LEO entrants, a theme that has played out in the price action this year.
The earnings history reinforces caution ahead of the November 11 print. The last two results both produced negative one-day moves, falling roughly 3.4% and 5.2% respectively, with the weakness persisting through the following week in both cases. That pattern is worth tracking rather than extrapolating, but it does set a higher bar for a positive surprise to shift the current tone.
Institutional ownership adds a layer of context. Israeli financial groups dominate the register. Phoenix Financial last disclosed an 11.4% stake (down from 14.2%), Migdal Insurance holds 10.7% (up from 8.5%), and Yelin Lapidot has grown its position to 7.1% from 5.4%. All filings are Schedule 13G, passive in nature, and all are event-driven disclosures that may not reflect current holdings. On the insider side, the 90-day net is a sale of roughly 21,500 shares worth $312,000, led by a discretionary CEO sale in March at prices well above where the stock trades today. No insider buying appears on the register in that window. Meanwhile, peers VSAT rose 7.7% on the week and UI gained 12%, making GILT's 7.2% decline a notable underperformer in its own correlation group.
The November 11 earnings date is now the focal point: whether the defence bookings that bulls are counting on show up in the numbers, and whether the borrow cost remains elevated into the release, will be the two things to track most closely.
See the live data behind this article on ORTEX.
Open GILT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
